TuHURA Biosciences Updates Portfolio Including VISTA Symposium In AML; $15.6M Financing Extends Runway For Key Phase 3 Milestones

Benzinga · 2d ago

Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026

A mini KOL symposium held on December 5, 2025, provided the scientific rational for targeting VISTA in AML and the clinical applications in combination with a menin inhibitor in NPM1 mutated relapsed/refractory AML

Oral and poster presentations at the recently concluded 57th ASH Annual Meeting showed the Delta Opioid Receptor (DOR) to be a compelling new target as the cornerstone for the Company's bi-functional, bi-specific immune modulating Antibody Drug Conjugates (ADCs)

Recent $15.6 million equity financing transaction provides cash runway to accomplish multiple key milestones across all three development programs

Management to host a call today, December 11, 2025, at 8:30 am ET

TAMPA, Fla., Dec. 11, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided updates across the company's portfolio of assets, including a summary from its mini symposium held on December 5, 2025 focused on targeting VISTA in AML, the scientific rational and clinical applications in NPM1 mutated r/r AML in combination with a menin inhibitor. The company's recently announced financing transaction, which provides for $15.6 million in gross proceeds, is expected to provide the cash runway to accomplish multiple key milestones across all three development programs.